KRAS and non-small cell lung carcinoma: Given that the full clinical history of the patients was not available, it is not possible to confirm whether the enrichment of ALK fusions, KRAS G12C, and MET amplification in the NSCLC-BM samples is due to longer survival of the patients having been treated with systemic therapy targeting these GAs.